Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 622-632

  Louie, Arnold ^a   Boyne, Michael T ^b   Patel, Vikram ^c   Huntley, Clayton ^d   Liu, Weiguo ^a   Fikes, Steven ^a   Kurhanewicz, Stephanie ^a   Rodriquez, Jaime ^a   Robbins, Nichole ^a   Brown, David ^a   Baluya, Dodge ^a   Drusano, G L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Office of Testing and Research   (United States)

^c Center for Drug Evaluation and Research   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EC50; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STAPHYLOCOCCUS INFECTION; UNITED STATES; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; INBRED MOUSE STRAIN; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PARENTERAL DRUG ADMINISTRATION; PRECLINICAL STUDY; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALS; BLOOD PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INFUSIONS, PARENTERAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES; VANCOMYCIN;

EID: 84920184721     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03710-14     Document Type: Article

References (19)

1. Code of Federal Regulations. 2011. Title 21. Food and drugs. Chapter 1.Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(3).
2. Code of Federal Regulations. 2011. Title 21. Food and drugs. Chapter 1. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a).
3. Nambiar S, Madurawe RD, Zuk SM, Khan SR, Ellison CD, Faustino PJ, Mans DJ, Trehy ML, Hadwiger ME, Boyne MT, II, Biswas K, Cox EM. 2012. Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother 56:2819-2823. http://dx.doi.org /10.1128/AAC.05344-11.
4. Hadwiger ME, Sommers CD, Mans DJ, Patel V, Boyne MT, II. 2012. Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectroscopy and potency assays. Antimicrob Agents Chemother 56:2824-2830. http://dx .doi.org/10.1128/AAC.00164-12.
5. USP. 2011. Antibiotics-microbial assays. United States pharmacopeia and national formulary. USP 34-NF 29. USP, Rockville, MD.
6. USP. 2011. Vancomycin HCl for injection. United States pharmacopeia and national formulary. USP 34-NF 29. USP, Rockville, MD.
7. Code of Federal Regulations. 2011. Title 21. Food and drugs. Chapter 1. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(9)(iii).
8. Code of Federal Regulations. 2011. Title 21. Food and drugs. Chapter 1. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(9).
9. Code of Federal Regulations. 2011. Title 21. Food and drugs. Chapter 1. Food and Drug Administration. Subchapter D. Drugs for human use. Part 320. Bioavailability and bioequivalence requirements. 21 CFR 320.22.
10. Lee SL, Yu LX, Cai B, Johnsons GR, Rosenberg AS, Cherney BW, Guo W, Raw AS. 2011. Scientific considerations for generic synthetic salmon calcitonin nasal spray. AAPS J 13: 14-19. http://dx.doi.org/10 .1208/s12248-010-9242-9.
11. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 54:3271-3279. http://dx.doi.org/10.1128/AAC.01044-09.
12. Eagle H, Musselman AD. 1948. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 88: 99-131. http://dx.doi.org/10.1084/jem.88.1.99.
13. Tattevin P, Saleh-Mghir A, Davido B, Ghout I, Massias L, Garcia de la Maria C, Miró JM, Perronne C, Laurent F, Crémieux AC. 2013. Comparison of six generic vancomycin products for treatment of methicillinresistant Staphylococcus aureus experimental endocarditis in rabbits. Antimicrob Agents Chemother 57:1157-1162. http://dx.doi.org/10.1128 /AAC.01669-12.
14. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, 8th ed. CLSI publication M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, approved standard M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
16. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
17. Leary R, Jelliffe R, Schumitzky A, Van Guilder M. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p 389-394. In Proceedings of the 14th IEEE Symposium on Com-puter-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
18. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479-501. http://dx.doi.org/10 .1016/S0891-5520(03)00065-5.
19. Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL. 2012. Evaluation of once-daily vancomycin against methi-cillin-resistant Staphylococcus aureus in a hollow fiber infection model. Antimicrob Agents Chemother 56:682-668. http://dx.doi.org/10.1128 /AAC.05664-11.